DMD Aileleri Derneği
Ankara, Çankaya, 06530, Turkey (Türkiye)
NCT Number: NCT06682585
Brief Summary
The goal of this clinical trial is to evaluate the impact of a disease-specific, individualized diet on the nutritional status and functional abilities of Duchenne muscular dystrophy (DMD) patients. The study will focus on children aged 4-8 years residing in Ankara, Turkey.
Key questions the investigators aim to answer:
Can a tailored dietary intervention improve the nutritional status of DMD patients? Does a specialized diet positively impact the functional abilities of DMD patients, as measured by the North Star Ambulation Assessment (NSAA)? Participants will undergo a comprehensive nutritional assessment, including anthropometric measurements, and will receive individualized dietary counseling. The intervention will focus on optimizing energy, protein, calcium, and fluid intake, as well as addressing the potential side effects of corticosteroid therapy.
The primary outcome measure will be changes in nutritional status, as assessed by anthropometric measurements. Secondary outcome measures will include changes in functional abilities as measured by the NSAA and quality of life assessments.
Looking for future studies?
Notify Me48 month–96 month
Male
Interventional
Not applicable
Ankara, Çankaya, 06530, Turkey (Türkiye)
Study Objective This study aims to investigate the efficacy of a disease-specific, individualized dietary intervention in improving the nutritional status and functional abilities of Duchenne Muscular Dystrophy (DMD) patients aged 4-8 years residing in Ankara, Turkey.
Study Design This is a prospective, interventional study. Intervention
A 12-week individualized dietary intervention will be implemented for each participant. The intervention will focus on:
Outcome Measures Changes in anthropometric measurements (body weight, height, BMI, skinfold measurements) Changes in functional abilities as assessed by the North Star Ambulation Assessment (NSAA) Changes in functional abilities as assessed by handgrip strenght Changes in micro and micro nutrient intake as assessed by three-day food consumption record Data Collection Data will be collected through face-to-face interviews with parents or primary caregivers and patients with DMD. After the first interview, a second interview will be conducted 12 weeks after the personalized diet has been planned.
Baseline Assessment:
Follow-up Assessments:
Ethical Considerations The study will be conducted in accordance with the Declaration of Helsinki and approved by the local ethics committee. Informed consent will be obtained from the parents or legal guardians of the participants.
By addressing the specific nutritional needs of DMD patients, this study aims to improve their overall health and quality of life.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Clinical diagnosis of Duchenne Muscular Dystrophy (DMD) Must be between 4 and 8 years old Able to ambulate independently Must be residing in Ankara province, Turkey Must be willing to participate and adhere to the dietary intervention, as confirmed by both the patient and their legal guardian(s) Must be currently receiving corticosteroid therapy
Exclusion criteria
Inability to read and write in Turkish Wheelchair-bound or unable to ambulate independently Significant liver or kidney dysfunction Scheduled for major surgery within 6 months of study enrollment Symptoms of dysphagia and swallowing difficulties Significant respiratory distress or respiratory insufficiency requiring mechanical ventilation.
Time frame: From enrollment to the end of diet at 12 weeks
Changes in body weight (kg). Body weight will be measured with an electronic scale sensitive to 0.1 kilograms.
Time frame: From enrollment to the end of diet at 12 weeks
Changes in skinfold thickness (triceps, biceps, subscapular, and suprailiac) (in millimeters) Skinfold thickness will be compared to the World Health Organization's percentile and Z score charts to determine adequacy, deficiency, or excess.
Time frame: From enrollment to the end of diet at 12 weeks
Changes in height (cm). Height is measured with the individual standing upright and the head in the Frankfurt plane (the orbitale point and tragion point are set to be on the horizontal plane), while the vertical distance from the ground to the vertex, which is the highest point of the head, will be measured with a tape measure on a fixed plane.
Time frame: From enrollment to the end of diet at 12 weeks
Changes in Body Mass Index (BMI)(kg/m²). BMI will be obtained by dividing the particioant's body weight in kg by the square of the height in meters.
Body mass index will be evaluated with the World Health Organization's percentile and Z score charts.
Time frame: From enrollment to the end of diet at 12 weeks
Changes in the North Star Ambulation Assessment (NSAA) score meausered by a specialist physiotherapist. The total score varies between 0-34. A higher score indicates better ambulation and motor function.
Time frame: From enrollment to the end of diet at 12 weeks
Changes in hand grip strength measured by hand dynamometry (in kilograms)
Time frame: From enrollment to the end of diet at 12 weeks
After the dietary intervention, 3-day food consumption records will be taken again. The 3-day food consumption records before and after the dietary intervention will be examined. The compatibility of the latest consumption records with the macro and micronutrients of the recommended diet and the differences between the first 3-day food consumption record will be examined. The computer program called BeBIS will be used for the analysis of macro and micronutrients.
Ankara University
Other
Determination of Nutritional Status of Duchenne Muscular Dystrophy Patients and Evaluation of the Effectiveness of Disease-Specific Nutrition Therapy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04322357
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Duchenne Muscular Dystrophy (DMD)
Gainesville, Florida, United States
View Trial DetailsNCT07437378
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Duchenne Muscular Dystrophy (DMD)
Minya, Menia Governorate, Egypt
View Trial DetailsNCT07317063
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Duchenne Muscular Dystrophy (DMD)
Newark, New Jersey, United States
View Trial DetailsNCT07338812
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Duchenne Muscular Dystrophy (DMD)
Cairo, Egypt
View Trial Details